View source for Chemistry:Odalasvir

{{Short description|Chemical compound}}
{{Infobox drug
| drug_name =
| IUPAC_name = Dimethyl ''N'',''N''<nowiki>'</nowiki>-(1,4(1,4)-dibenzenacyclohexaphane- 1<sup>2</sup>,4<sup>2</sup>-diylbis{1''H''-benzimidazole-5,2-diyl[(2''S'',3a''S'',7a''S'')- octahydro-1''H''-indole-2,1-diyl] [(2''S'')-3-methyl-1-oxobutan- 1,2-diyl]})biscarbamate
| image = Odalasvir structure.svg
| width = 300
| alt =
| caption =

<!-- Clinical data -->
| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = Investigational New Drug
| legal_status =
| routes_of_administration =

<!-- Pharmacokinetic data -->
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 1415119-52-6
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = OVR52K7BDW
| ATCvet =
| ATC_prefix =
| ATC_suffix =
| PubChem = 71474517
| DrugBank =
| ChemSpiderID = 34500837
| ChEMBL =

<!-- Chemical data -->
| chemical_formula =
| C=60 | H=72 | N=8 | O=6
| StdInChIKey = LSYBRGMTRKJATA-IVEWBXRVSA-N
| StdInChI = 1S/C60H72N8O6/c1-33(2)53(65-59(71)73-5)57(69)67-49-13-9-7-11-41(49)31-51(67)55-61-45-25-23-39(29-47(45)63-55)43-27-35-15-19-37(43)21-17-36-16-20-38(22-18-35)44(28-36)40-24-26-46-48(30-40)64-56(62-46)52-32-42-12-8-10-14-50(42)68(52)58(70)54(34(3)4)66-60(72)74-6/h15-16,19-20,23-30,33-34,41-42,49-54H,7-14,17-18,21-22,31-32H2,1-6H3,(H,61,63)(H,62,64)(H,65,71)(H,66,72)/t41-,42-,49-,50-,51-,52-,53-,54-/m0/s1
| smiles = CC(C)[C@@H](C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C3=NC4=C(N3)C=C(C=C4)C5=C6CCC7=CC(=C(CCC(=C5)C=C6)C=C7)C8=CC9=C(C=C8)N=C(N9)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
}}

'''Odalasvir''' (INN,<ref>{{cite web|title=International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names: List 73|url=https://www.who.int/medicines/publications/druginformation/innlists/RL73_pre.pdf|website=who.int|publisher=World Health Organization|access-date=5 December 2015|page=38}}</ref> previously known as '''ACH-3102''')<ref>{{cite web|title=Achillion Has Discovered and Developed a Comprehensive Portfolio of Antivirals for the Treatment of Hepatitis C|url=http://www.achillion.com/ACH3102|publisher=Achillion Pharmaceuticals|access-date=15 November 2015}}</ref><ref>{{cite web | url = https://chem.nlm.nih.gov/chemidplus/rn/1415119-52-6 | title = Odalasvir | work = ChemIDplus }}</ref> is an investigational new drug in development for the treatment of [[Medicine:Hepatitis C|hepatitis C]].<ref>{{Cite journal |last=Walker |first=Tracey | name-list-style = vanc |date=December 2015 |title=Watch list 2016: top therapeutic areas: experts say you should follow these 6 therapeutic areas.|url=http://go.galegroup.com/ps/i.do?id=GALE%7CA440401487&v=2.1&it=r&p=GPS&sw=w&asid=711ead20380f089d56147e239e6804ca|journal=Managed Healthcare Executive|page=47|access-date=March 12, 2016}}</ref>  It is an NS5A inhibitor.<ref name="pmid24659881">{{cite journal | vauthors = Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O | title = Hepatitis C virus NS5A inhibitors and drug resistance mutations | journal = World Journal of Gastroenterology | volume = 20 | issue = 11 | pages = 2902–12 | date = March 2014 | pmid = 24659881 | pmc = 3961994 | doi = 10.3748/wjg.v20.i11.2902 | doi-access = free }}</ref> The NS5A protein serves multiple functions at various stages of the viral life cycle, including [[Biology:Viral replication|viral replication]]. NS5A also plays a role in the development of [[Biology:Interferon|interferon]]-resistance, a common cause of treatment failure.<ref>{{cite web | url = http://www.achillion.com/ACH3102_resources | title = ACH-3102 resources | publisher = Achillion Pharmaceuticals | date = Winter 2011 | access-date = 1 May 2012 }}</ref><ref>{{cite web | url = http://www.businessweek.com/ap/2012-05/D9UP7TCG0.htm | archive-url = https://web.archive.org/web/20120522020801/http://www.businessweek.com/ap/2012-05/D9UP7TCG0.htm | url-status = dead | archive-date = May 22, 2012 | title = Achillion gets FDA incentives for hepatitis C drug | agency = Associated Press | date = 15 May 2012 }}</ref><ref>{{cite conference | last = Levin | first = Jules | name-list-style = vanc |url= http://www.natap.org/2012/EASL/EASL_79.htm |title= Preclinical characteristics of ACH-3102 |date= 18–22 April 2012 |conference=  47th Annual Meeting |publisher= European Association for the Study of the Liver |location= Barcelona, Spain }}</ref> It is under [[Medicine:Drug development|development]] by Achillion Pharmaceuticals.{{cn|date=January 2023}}

==See also==
* Discovery and development of NS5A inhibitors

==References==
{{Reflist}}

{{RNA antivirals}}

[[Category:Benzimidazoles]]
[[Category:Carbamates]]
[[Category:Cyclophanes]]


{{Sourceattribution|Odalasvir}}